Genes behind deadly heart condition found, scientists say
Scientists say they have identified genes that cause a deadly heart condition that can only be cured by transplants of the heart or lungs. Pulmonary arterial hypertension kills 50% of those affected within five years, but little was known about what caused the condition in some people.
Johns Hopkins Investigators Unravel Biological Roots of Pulmonary Hypertension
Working with cells that line the innermost layer of the blood vessels, Johns Hopkins investigators say they have made a leap forward in understanding the underlying biology behind pulmonary hypertension, a dangerous type of high blood pressure in lungs that ultimately leads to right heart failure and death. By conducting experiments in endothelial cells, they discovered that a protein called KLF15 (Kruppel-like factor 15) protects these cells …
N.S. patient raising $45,000 to cover cost of living near Toronto transplant hospital
HALIFAX — Meaghan Barnhill is struggling to raise $45,000 to pay for accommodations in Toronto where a life-saving double-lung transplant will take place, but she’s already looking for ways to pay it forward. The 29-year-old was diagnosed with pulmonary arterial hypertension two years ago. The rare, progressively debilitating disease has left her unable to work or do much of anything.
International Women's Day: Paying It Forward
Over the course of my years living with pulmonary hypertension (PH), I have had the chance to witness and experience women’s ability to help one another and lift each other out of tough situations. I was first diagnosed in 2009 and went through a long period of denial. It wasn’t until I decided to go to a support group, at the suggestion of my nurse Lyda Lesenko, that I noticed the obvious abundance of women in our community. There I was approach…
First province begins funding new life-extending treatment for patients with rare lung disease
Vancouver, BC/Hamilton, ON (Tuesday, March 6, 2018) – The Pulmonary Hypertension Association of Canada (PHA Canada) and Scleroderma Canada (SC) were unanimous today in their praise of the Quebec government for swiftly providing public funding for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). Effective as of March 1, 2018, this action stems from the recent conclusion of pricing negotiations for Uptravi by the pan-…
Kidney Disease Patients with Pulmonary Hypertension Face Poorer Outcomes, Study Finds
Many people with chronic kidney disease also have pulmonary hypertension, a condition that increases their risk of heart problems and death, a review of 16 studies found. Doctors refer to health problems that can damage the heart muscle as cardiovascular events. They include a heart attack, an irregular heartbeat, or a blood clot in the heart or lungs.
Idiopathic PAH-Associated Hypoxemia Linked to Poor Survival, Increased Comorbidities
Hypoxemia in individuals with heritable pulmonary arterial hypertension (HPAH) or idiopathic PAH (IPAH) is associated with increased mortality risk, a greater number of comorbidities, and reduced precapillary pulmonary hypertension severity than in patients without hypoxemia, according to findings from a retrospective study published in PLoS One.
Tracleer Increased Survival of Patients with Pulmonary Hypertension Due to IPF, Trial Shows
Actelion Pharmaceuticals’ Tracleer (bosentan) increased the overall survival and reduced the hospitalizations of patients with pulmonary hypertension stemming from idiopathic pulmonary fibrosis, or IPF-PH, a Japanese clinical trial shows.
#TakeActionPAH: Making UPTRAVI available to all Canadians
This month – two years after the bad news about the Opsumit© negotiations – pCPA announced that a pricing agreement has been reached for Uptravi©. This now creates the conditions for individual provinces and territories to immediately make Uptravi© available to patients in need through their public drug plans. We aren’t there just yet – and we will still need your help to get over the finish line – but today we deserve to celebrate this important…
Study on Pulmonary Arterial Hypertension treatment tool exceeds 100 patient enrolment
A clinical-stage biotherapeutics company today announced that enrollment in its Phase 3 INOvation-1 study evaluating INOpulse® in patients with pulmonary arterial hypertension (PAH) now exceeds 100 patients, representing more than half of the anticipated enrollment.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter